Galantamine and behavior in Alzheimer disease: Analysis of four trials

Acta Neurologica Scandinavica

Volumn 124, Issue 5, 2011, Pages 302-308

  Kavanagh, S ^a   Gaudig, M ^b   Van Baelen, B ^c   Adami, M ^d   Delgado, A ^e   Guzman, C ^f   Jedenius, E ^g   Schauble B ^b  

^a JOHNSON AND JOHNSON   (United States)

^b JANSSEN CILAG GMBH   (Germany)

^c SGS Medisearch International NV   (Belgium)

^d Janssen Cilag SpA Italia   (Italy)

^e Janssen Cilag   (France)

^f Janssen Cilag   (Spain)

^g Janssen Cilag   (Sweden)

Author keywords

Alzheimer's disease; Behavior; Caregivers; Galantamine; Randomized controlled trials

Indexed keywords

GALANTAMINE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CAREGIVER BURDEN; DEPRESSION; DISEASE SEVERITY; DYSPHORIA; HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; MALE; MENTAL DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80053563110     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01525.x     Document Type: Article

References (28)

1. Tariot PN, Podgorski CA, Blazina L, Leibovici A. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993;150:1063-9.
2. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009;21:813-24.
3. Shimabukuro J, Awata S, Matsuoka H. Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients. Psychiatry Clin Neurosci 2005;59:274-9.
4. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-5.
5. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6:S64-78.
6. Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Alzheimers Dement 2008;4:49-60.
7. Black W, Almeida OP. A systematic review of the association between the Behavioral and Psychological Symptoms of Dementia and burden of care. Int Psychogeriatr 2004;16:295-315.
8. Rymer S, Salloway S, Norton L, Malloy P, Correia S, Monast D. Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord 2002;16:248-53.
9. Phillips VL, Diwan S. The incremental effect of dementia-related problem behaviors on the time to nursing home placement in poor, frail, demented older people. J Am Geriatr Soc 2003;51:188-93.
10. Yaffe K, Fox P, Newcomer R et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002;287:2090-7.
11. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162:1996-2021.
12. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD003476.
13. Gill SS, Bronskill SE, Normand SL et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-86.
14. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176:627-32.
15. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
16. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76.
17. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:120-32.
18. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
21. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48(Suppl. 6):S10-6.
22. Herrmann N, Rabheru K, Wang J, Binder C. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005;13:527-34.
23. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007;69:448-58.
24. Cook C, Fay S, Rockwood K. Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. Int Psychogeriatr 2008;20:952-63.
25. Waldemar G, Gauthier S, Jones R et al. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2011;26:150-7.
26. Gauthier S, Feldman H, Hecker J et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14:389-404.
27. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
28. Feldman HH, Pirttila T, Dartigues JF et al. Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurol Scand 2009;119:22-31.